Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

When asked today if Ireland will follow such a move, the health minister said Mounjaro, “is going through the reimbursement ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast ...

Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why ...

The stock market rose within a mini-range for the week amid Israel-Iran headlines and the Federal Reserve's rate outlook.

The global Parkinson's disease drugs market size is projected to reach $10.4 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031.

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...

While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle ...